The oral multikinase inhibitor sunitinib malate was approved by the US Food and Drug
Administration in January 2006 for use in patients with advanced renal cell carcinoma …

Introduction: Over the past decade, a greater understanding into the molecular pathogenesis
of renal cell carcinoma (RCC) has led to major advances in treatment options. Sunitinib is an …

Sunitinib is a reference standard of care for the treatment of metastatic renal cell carcinoma
(mRCC). While the tolerability of sunitinib is consistent across clinical studies, the impact of …

Introduction: Sunitinib is a multi-target, anti-angiogenic tyrosine kinase inhibitor and a key
molecule in the treatment of metastatic renal cell carcinoma (mRCC). Since it first …

Targeted agents have improved prognosis for patients with metastatic renal cell carcinoma
(mRCC), and they are changing therapeutic expectations with respect to long-term clinical …

Following approval of the oral, multitargeted tyrosine kinase inhibitor sunitinib malate for the
treatment of patients with metastatic renal cell carcinoma (mRCC) in Europe and the USA in …

Sunitinib is a multitarget tyrosine kinase inhibitor endowed mainly by antiangiogenic effects,
although an indirect inhibitory effect on tumor growth and, more recently, a complex activity …

Objective This prospective, post-marketing study collected sunitinib safety and efficacy data
in Japanese patients with unresectable/metastatic renal cell carcinoma. Retrospective …

Sunitinib is an orally administered multitargeted tyrosine kinase inhibitor approved
multinationally for the first-and second-line treatment of metastatic renal cell carcinoma …

Study Type–Therapy (case series) Level of Evidence 4 What's known on the subject? and
What does the study add? Sunitinib is approved for the first‐and second‐line treatment of …